Immunization of HIV-infected adult patients — French recommendations

References

• Haut Conseil de la Santé Publique. Vaccinations des personnes immunodéprimées ou aspléniques. Recommandations 2012 Available from: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=322
   Google Scholar
• HCSP. Vaccination des personnes immunodéprimées ou aspléniques. Recommandations actualisées. Paris: Haut Conseil de la Santé Publique 2014 Available from: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=504
   Google Scholar
• Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis Off Publ Infect Dis Soc Am 2014 Feb; 58(3):309-18; http://dx.doi.org/10.1093/cid/cit816
   PubMed Web of Science ®Google Scholar
• Menson EN, Mellado MJ, Bamford A, Castelli G, Duiculescu D, Marczyńska M, Navarro M, Scherpbier HJ, Heath PT. Guidance on vaccination of HIV-infected children in Europe. HIV Med 2012 Jul; 13(6):333-6; e1-14; http://dx.doi.org/10.1111/j.1468-1293.2011.00982.x
   PubMed Web of Science ®Google Scholar
• EACS Guidelines 8.0
   Google Scholar
• Glesby MJ. Immunizations during HIV infection. Curr Opin Infect Dis 1998 Feb; 11(1):17-21; http://dx.doi.org/10.1097/00001432-199802000-00005
   PubMed Web of Science ®Google Scholar
• Valour F, Cotte L, Voirin N, Godinot M, Ader F, Ferry T, Vanhems P, Chidiac C. Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine 2014 Jul 31; 32(35):4558-64; PMID:24951870; http://dx.doi.org/10.1016/j.vaccine.2014.06.015
   PubMed Web of Science ®Google Scholar
• Guthmann JP, Fonteneau L, Collet M, Vilain A, Ragot M, Ben Boutlieb M, et al. Couverture vaccinale des enfants et des adolescents en France : résultats des enquêtes menées en milieu scolaire, 2001-2004 Vaccination coverage of children and adolescents in France: results of school-based surveys, 2001-2004 - Google Scholar [Internet]. BEH 2015 [cited 2016 May 18]. Available from: http://opac.invs.sante.fr/index.php?lvl=more_results&autolevel1=1
   Google Scholar
• Martins S, Livramento Ad, Andrigueti M, Kretzer IF, Machado MJ, Spada C, Treitinger A. Vaccination coverage and immunity against hepatitis B among HIV-infected patients in South Brazil. Braz J Infect Dis Off Publ Braz Soc Infect Dis 2015 Apr; 19(2):181-6
   PubMed Web of Science ®Google Scholar
• Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M, et al. Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. PloS One 2012; 7(11):e49314; PMID:23145150; http://dx.doi.org/10.1371/journal.pone.0049314
   PubMedGoogle Scholar
• Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 2008 Nov; 12(6):e77-83
   PubMed Web of Science ®Google Scholar
• Guthmann JP, Fonteneau L, Bonmarin I, Lévy-Bruhl D. Influenza vaccination coverage one year after the A(H1N1) influenza pandemic, France, 2010-2011. Vaccine 2012 Feb 1; 30(6):995-7; PMID:22178520; http://dx.doi.org/10.1016/j.vaccine.2011.12.011
   PubMed Web of Science ®Google Scholar
• Durham MD, Buchacz K, Armon C, Patel P, Wood K, Brooks JT, HIV Outpatient Study (HOPS) Investigators. Seasonal Influenza Vaccination Rates in the HIV Outpatient Study—United States, 1999-2013. Clin Infect Dis 2015 Mar 15; 60(6):976-7; PMID:25501987; http://dx.doi.org/10.1093/cid/ciu979
   PubMed Web of Science ®Google Scholar
• Cotte L, Voirin N, Richard C, Brochier C, Schlienger I, Lack P, Lina B, Vanhems P, Zoulim F. Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients. Vaccine 2011 Aug 5; 29(34):5638-44; PMID:21699948; http://dx.doi.org/10.1016/j.vaccine.2011.06.013
   PubMed Web of Science ®Google Scholar
• Mohseni-Zadeh M, Rey D, Batard ML, Beck Wirth G, Partisani ML, Lang JM, Hansmann Y, Christmann D, Martinot M. Inadequate vaccination coverage in a French cohort of HIV positive patients. Médecine Mal Infect 2010 Dec; 40(12):683-90; PMID:20822870
   PubMed Web of Science ®Google Scholar
• Guthmann JP. Enquête nationale de couverture vaccinale, France, janvier 2011. Couverture vaccinale contre la grippe saisonnière dans les groupes cibles et mesure de l’efficacité vaccinale. Couverture vaccinale par les vaccins diphtérie-tétanos-poliomyélite (dTP) et antipneumococcique chezles personnes âgées de 65 ans et plus. Saint-Maurice: Institut de veille sanitaire 2011; 21
   Google Scholar
• Grabmeier-Pfistershammer K, Herkner H, Touzeau-Roemer V, Rieger A, Burgmann H, Poeppl W. Low tetanus, diphtheria and acellular pertussis (Tdap) vaccination coverage among HIV infected individuals in Austria. Vaccine [Internet]. [cited 2015 Jul 9]; Available from: http://www.sciencedirect.com/science/article/pii/S0264410´15008579
   Web of Science ®Google Scholar
• Grabmeier-Pfistershammer K, Poeppl W, Herkner H, Touzeau-Roemer V, Huschka E, Rieger A, et al. High need for MMR vaccination in HIV infected adults in Austria. Vaccine 2014 Oct 14; 32(45):6020-3; PMID:25203449; http://dx.doi.org/10.1016/j.vaccine.2014.07.114
   PubMed Web of Science ®Google Scholar
• Gagneux-Brunon A, Lucht F, Botelho-Nevers E. HIV care: A missed opportunity for immunization. Vaccine 2016; 34(32):3632 Mar 19;; PMID:27002502
   PubMed Web of Science ®Google Scholar
• Mullaert J, Abgrall S, Lele N, Batteux F, Slama LB, Meritet JF, Lebon P, Bouchaud O, Grabar S, Launay O, et al. Diphtheria, tetanus, poliomyelitis, yellow fever and hepatitis B seroprevalence among HIV1-infected migrants. Results from the ANRS VIHVO vaccine sub-study. Vaccine 2015 Sep 11; 33(38):4938-44; PMID:26209841; http://dx.doi.org/10.1016/j.vaccine.2015.07.036
   PubMed Web of Science ®Google Scholar
• Bonetti TC, Succi RC, Weckx LY, Tavares-Lopes L, de Moraes-Pinto MI. Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women. Vaccine 2004 Sep 9; 22(27-28):3707-12; PMID:15315850; http://dx.doi.org/10.1016/j.vaccine.2004.03.023
   PubMed Web of Science ®Google Scholar
• Dieye TN, Sow PS, Simonart T, Guèye-Ndiaye A, Popper SJ, Delforge ML, Dieye A, Sarr AD, Crusiaux A, Van Vooren JP, et al. Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals. Vaccine 2001 Dec 12; 20(5-6):905-13; PMID:11738756; http://dx.doi.org/10.1016/S0264-410X(01)00383-8
   PubMed Web of Science ®Google Scholar
• Andrade RM, Andrade AF, Lazaro MA, Vieira MM, Barros PO, Borner AR, Silva-Filho RG, Santos JO, Brindeiro RM, Tanuri A, et al. Failure of highly active antiretroviral therapy in reconstituting immune response to Clostridium tetani vaccine in aged AIDS patients. J Acquir Immune Defic Syndr 1999 2010 May 1; 54(1):10-7; PMID:20224419
   PubMed Web of Science ®Google Scholar
• Kernéis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boëlle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am 2014 Apr; 58(8):1130-9; http://dx.doi.org/10.1093/cid/cit937
   PubMed Web of Science ®Google Scholar
• Redd SC, Rutherford GW, Sande MA, Lifson AR, Hadley WK, Facklam RR, Spika JS. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis. 1990 Nov; 162(5):1012-7; PMID:2230229; http://dx.doi.org/10.1093/infdis/162.5.1012
   PubMed Web of Science ®Google Scholar
• Jordano Q, Falcó V, Almirante B, Planes AM, del Valle O, Ribera E, Len O, Pigrau C, Pahissa A. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am 2004 Jun 1; 38(11):1623-8; http://dx.doi.org/10.1086/420933
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Larsen MV, Ladelund S, Kronborg G, Konradsen HB, Gerstoft J, Larsen CS, Pedersen C, Pedersen G, Obel N, et al. Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users. Clin Infect Dis Off Publ Infect Dis Soc Am 2014 Oct 15; 59(8):1168-76; http://dx.doi.org/10.1093/cid/ciu558
   PubMed Web of Science ®Google Scholar
• Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, Smith RD, Slack M, Delpech VC. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS Lond Engl 2012 Jan 2; 26(1):87-94; http://dx.doi.org/10.1097/QAD.0b013e32834dcf27
   PubMed Web of Science ®Google Scholar
• Grau I, Ardanuy C, Liñares J, Podzamczer D, Schulze MH, Pallares R. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med 2009 Sep; 10(8):488-95; PMID:19459987; http://dx.doi.org/10.1111/j.1468-1293.2009.00717.x
   PubMed Web of Science ®Google Scholar
• Peñaranda M, Falco V, Payeras A, Jordano Q, Curran A, Pareja A, Samperiz G, Dalmau D, Ribera E, Riera M. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis Off Publ Infect Dis Soc Am 2007 Oct 1; 45(7):e82-7; http://dx.doi.org/10.1086/520977
   PubMed Web of Science ®Google Scholar
• French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet Lond Engl 2000 Jun 17; 355(9221):2106-11; http://dx.doi.org/10.1016/S0140-6736(00)02377-1
   PubMed Web of Science ®Google Scholar
• Pedersen RH, Lohse N, Østergaard L, Søgaard OS. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med. 2011 Jul; 12(6):323-33; PMID:21059168; http://dx.doi.org/10.1111/j.1468-1293.2010.00892.x
   PubMed Web of Science ®Google Scholar
• Hung CC, Chang SY, Su CT, Chen YY, Chang SF, Yang CY, Liu WC, Wu CH, Chang SC. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med 2010 Jan; 11(1):54-63; PMID:19659943; http://dx.doi.org/10.1111/j.1468-1293.2009.00744.x
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra EE, Molyneux ME, Gilks CF. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010 Mar 4; 362(9):812-22; PMID:20200385; http://dx.doi.org/10.1056/NEJMoa0903029
   PubMed Web of Science ®Google Scholar
• Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccines Immunother 2012 Feb; 8(2):161-73; http://dx.doi.org/10.4161/hv.18432
   PubMed Web of Science ®Google Scholar
• Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS Lond Engl 2015 Jul 17; 29(11):1345-54; http://dx.doi.org/10.1097/QAD.0000000000000689
   PubMed Web of Science ®Google Scholar
• Bamford A, Kelleher P, Lyall H, Haston M, Zancolli M, Goldblatt D, Kampmann B. Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection. AIDS Lond Engl 2014 Sep 10; 28(14):2033-43; http://dx.doi.org/10.1097/QAD.0000000000000385
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, Sundaraiyer V, Natuk R, Gurtman A, Scott DA, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine. J Infect Dis. 2015 Jul 1; 212(1):18-27; PMID:25395187
   PubMed Web of Science ®Google Scholar
• Lesprit P, Pédrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, Katlama C, Yéni P, Morineau P, Delfraissy JF, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS Lond Engl 2007 Nov 30; 21(18):2425-34; http://dx.doi.org/10.1097/QAD.0b013e3282887e91
   PubMed Web of Science ®Google Scholar
• Fine AD, Bridges CB, De Guzman AM, Glover L, Zeller B, Wong SJ, Baker I, Regnery H, Fukuda K. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis Off Publ Infect Dis Soc Am 2001 Jun 15; 32(12):1784-91; http://dx.doi.org/10.1086/320747
   PubMed Web of Science ®Google Scholar
• Klein MB, Lu Y, DelBalso L, Coté S, Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis Off Publ Infect Dis Soc Am 2007 Jul 15; 45(2):234-40; http://dx.doi.org/10.1086/518986
   PubMed Web of Science ®Google Scholar
• Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001 Feb 12; 161(3):441-6; PMID:11176770; http://dx.doi.org/10.1001/archinte.161.3.441
   PubMedGoogle Scholar
• Neuzil KM, Coffey CS, Mitchel EF, Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune DeficSyndr 1999 2003 Nov 1; 34(3):304-7; PMID:14600576; http://dx.doi.org/10.1097/00126334-200311010-00008
   PubMed Web of Science ®Google Scholar
• Cohen C, Simonsen L, Sample J, Kang JW, Miller M, Madhi SA, Campsmith M, Viboud C. Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. Clin Infect Dis Off Publ Infect Dis Soc Am 2012 Oct; 55(7):996-1003; http://dx.doi.org/10.1093/cid/cis549
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009 Aug; 9(8):493-504; PMID:19628174; http://dx.doi.org/10.1016/S1473-3099(09)70175-6
   PubMed Web of Science ®Google Scholar
• Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999 Sep 21; 131(6):430-3; PMID:10498559; http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00006
   PubMed Web of Science ®Google Scholar
• Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med 2008 Jan; 9(1):57-61; PMID:18199173; http://dx.doi.org/10.1111/j.1468-1293.2008.00515.x
   PubMed Web of Science ®Google Scholar
• Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, Pialoux G, Ghosn J, Raffi F, Rey D, et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 2011 Jul 1; 204(1):124-34; PMID:21628666; http://dx.doi.org/10.1093/infdis/jir211
   PubMed Web of Science ®Google Scholar
• Durier C, Desaint C, Lucht F, Girard PM, Lévy Y, May T, Michelet C, Rami A, Roman F, et al. Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults. AIDS Lond Engl 2013 Jan 2; 27(1):87-93; http://dx.doi.org/10.1097/QAD.0b013e328359f27a
   PubMed Web of Science ®Google Scholar
• Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, Cohen C, Valette M, Cutland CL, Sanne I. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis Off Publ Infect Dis Soc Am 2011 Jan 1; 52(1):128-37; http://dx.doi.org/10.1093/cid/ciq004
   PubMed Web of Science ®Google Scholar
• Remschmidt C, Wichmann O, Harder T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine 2014 Sep 29; 32(43):5585-92; PMID:25131742; http://dx.doi.org/10.1016/j.vaccine.2014.07.101
   PubMed Web of Science ®Google Scholar
• Skiest DJ, Machala T. Comparison of the effects of acute influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts. J Clin Virol Off Publ Pan Am Soc Clin Virol 2003 Apr; 26(3):307-15; http://dx.doi.org/10.1016/S1386-6532(02)00047-1
   PubMed Web of Science ®Google Scholar
• Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, Girard PM, Bélarbi L, Guérin C, Dimet J, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 1999 2008 Nov 1; 49(3):272-5; PMID:18845961; http://dx.doi.org/10.1097/QAI.0b013e318183a9c0
   PubMed Web of Science ®Google Scholar
• Mena G, García-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: A review. Hum Vaccines Immunother 2015; 11(11):2582-98; PMID:26208678; http://dx.doi.org/10.1080/21645515.2015.1055424
   PubMed Web of Science ®Google Scholar
• Tseng YT, Chang SY, Liu WC, Sun HY, Wu CH, Wu PY, Lu CL, Hung CC, Chang SC. Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. Hepatol Baltim Md 2013 May; 57(5):1734-41; http://dx.doi.org/10.1002/hep.26210
   PubMed Web of Science ®Google Scholar
• Kernéis S, Desaint C, Brichler S, Rey D, Belarbi L, Gordien E, Pacanowski J, Lortholary O, Abgrall S, Boëlle PY, et al. Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults. J Acquir Immune Defic Syndr 1999 2011 Jul 1; 57(3):e63-6; http://dx.doi.org/10.1097/QAI.0b013e31821fdec3
   Google Scholar
• Crum-Cianflone NF, Wilkins K, Lee AW, Grosso A, Landrum ML, Weintrob A, Ganesan A, Maguire J, Klopfer S, Brandt C, et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011 Jun 15; 203(12):1815-23; PMID:21606540; http://dx.doi.org/10.1093/infdis/jir180
   PubMed Web of Science ®Google Scholar
• Larsen C, Pialoux G, Salmon D, Antona D, Le Strat Y, Piroth L, Pol S, Rosenthal E, Neau D, Semaille C, et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill Bull Eur Sur Mal TransmEur Commun Dis Bull 2008 May 29; 13(22)
   Google Scholar
• Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis Off Publ Infect Dis Soc Am 2005 Oct 1; 41(7):1045-8; http://dx.doi.org/10.1086/433180
   PubMed Web of Science ®Google Scholar
• Cheeseman SH, Davaro RE, Ellison RT. Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med. 1996 May 9; 334(19):1272; PMID:8606735; http://dx.doi.org/10.1056/NEJM199605093341916
   PubMed Web of Science ®Google Scholar
• Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS Lond Engl 1994 Apr; 8(4):558-9; PMID:7912087; http://dx.doi.org/10.1097/00002030-199404000-00024
   PubMed Web of Science ®Google Scholar
• Mena G, Llupià A, García-Basteiro AL, Díez C, León A, García F, Bayas JMs. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine 2012 May 21; 30(24):3703-9; PMID:22446635; http://dx.doi.org/10.1016/j.vaccine.2012.03.018
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, Sivamurthy R, Sax PE, Ukomadu C. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005 May 1; 191(9):1435-41; PMID:15809901; http://dx.doi.org/10.1086/429302
   PubMed Web of Science ®Google Scholar
• Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005 Apr 22; 23(22):2902-8; PMID:15780739; http://dx.doi.org/10.1016/j.vaccine.2004.11.057
   PubMed Web of Science ®Google Scholar
• Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, Colin de Verdière N, Slama L, Martin K, Lortholary O, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011 Apr 13; 305(14):1432-40; PMID:21486976; http://dx.doi.org/10.1001/jama.2011.351
   PubMed Web of Science ®Google Scholar
• Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PloS One 2013; 8(11):e80409; PMID:24265819; http://dx.doi.org/10.1371/journal.pone.0080409
   PubMed Web of Science ®Google Scholar
• Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis 2015 Nov; 15(11):1283-91; PMID:26257021; http://dx.doi.org/10.1016/S1473-3099(15)00220-0
   PubMed Web of Science ®Google Scholar
• Sheng WH, Chuang YC, Sun HY, Tsai MS, Chang SY, Hung CC, Chang SC. Prophylactic effect of lamivudine-based antiretroviral therapy on incident hepatitis B virus infection among HIV-infected patients. Clin Infect Dis Off Publ Infect Dis Soc Am 2013 Nov; 57(10):1504-6; http://dx.doi.org/10.1093/cid/cit511
   PubMed Web of Science ®Google Scholar
• Chakvetadze C, Bani-Sadr F, Le Pendeven C, Lescure FX, Fontaine C, Galperine T, Slama L, Bonnard P, Mariot P, Soussan P, et al. Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen. Clin Infect Dis Off Publ Infect Dis Soc Am 2010 Apr 15; 50(8):1184-6; http://dx.doi.org/10.1086/651422
   PubMed Web of Science ®Google Scholar
• Piroth L, Launay O, Michel ML, Bourredjem A, Miailhes P, Ajana F, Chirouze C, Zucman D, Wendling MJ, Nazzal D, et al. Vaccination against hepatitis B Virus (HBV) in HIV-1-infected patients with isolated Anti-HBV core antibody: The ANRS HB EP03 CISOVAC prospective study. J Infect Dis 2016; 213(11):1735-42 Jan 14; PMID:26768256
   PubMed Web of Science ®Google Scholar
• Miller L, Arakaki L, Ramautar A, Bodach S, Braunstein SL, Kennedy J, Steiner-Sichel L, Ngai S, Shepard C, Weiss D. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med 2014 Jan 7; 160(1):30-7; PMID:24166695; http://dx.doi.org/10.7326/0003-4819-160-1-201401070-00731
   PubMed Web of Science ®Google Scholar
• Kratz MM, Weiss D, Ridpath A, Zucker JR, Geevarughese A, Rakeman J, Varma JK. Community-based outbreak of neisseria meningitidis serogroup c infection in men who have sex with men, New York City, New York, USA, 2010-2013. Emerg Infect Dis 2015 Aug; 21(8):1379-86
   PubMed Web of Science ®Google Scholar
• HCSP. Vaccination contre les infections invasives à méningocoque C au-delà de 24 ans, notamment chez les hommes ayant des relations sexuelles avec d’autres hommes (HSH)[Internet]. Paris: Haut Conseil de la Santé Publique; 2014 Nov [cited 2016 May 17]. Available from: http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=474
   Google Scholar
• Ridpath A, Greene SK, Robinson BF, Weiss D, Meningococcal Investigation Team. Risk Factors for Serogroup C meningococcal disease during outbreak among men who have sex with men, New York City, New York, USA. Emerg Infect Dis 2015 Aug; 21(8):1458-61; PMID:26196855; http://dx.doi.org/10.3201/eid2108.141932
   PubMed Web of Science ®Google Scholar
• Bertolini DV, Costa LS, van der Heijden IM, Sato HK, Marques HH. Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults. Vaccine 2012 Aug 10; 30(37):5482-6; PMID:22771509; http://dx.doi.org/10.1016/j.vaccine.2012.06.069
   PubMed Web of Science ®Google Scholar
• Frota AC, Milagres LG, Harrison LH, Ferreira B, Menna Barreto D, Pereira GS, Cruz AC, Pereira-Manfro W, de Oliveira RH, Abreu TF, et al. Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil. Pediatr Infect Dis J 2015 May; 34(5):e113-8; PMID:25876102; http://dx.doi.org/10.1097/INF.0000000000000630
   PubMedGoogle Scholar
• Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, et al. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J 2010 May; 29(5):391-6; PMID:20431379; http://dx.doi.org/10.1097/INF.0b013e3181c38f3b
   PubMed Web of Science ®Google Scholar
• Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, et al. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr 2012 Oct; 161(4):676-81.e2; PMID:22622049; http://dx.doi.org/10.1016/j.jpeds.2012.04.005
   PubMed Web of Science ®Google Scholar
• Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, Hillman RJ, Petoumenos K, Roberts J, Tabrizi SN. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012 May; 13(5):487-500; PMID:22445259; http://dx.doi.org/10.1016/S1470-2045(12)70080-3
   PubMed Web of Science ®Google Scholar
• Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort.. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009 Dec; 10(12):1152-9; PMID:19818686; http://dx.doi.org/10.1016/S1470-2045(09)70282-7
   PubMed Web of Science ®Google Scholar
• Bratcher LF, Sahasrabuddhe VV. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer 2010; 5:8; PMID:20462441; http://dx.doi.org/10.1186/1750-9378-5-8
   PubMedGoogle Scholar
• Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011 May 4; 103(9):753-62; PMID:21483021; http://dx.doi.org/10.1093/jnci/djr076
   PubMedGoogle Scholar
• Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011 Oct 27; 365(17):1576-85; PMID:22029979; http://dx.doi.org/10.1056/NEJMoa1010971
   PubMed Web of Science ®Google Scholar
• Giacomet V, Penagini F, Trabattoni D, Vigan∫ A, Rainone V, Bernazzani G, Bonardi CM, Clerici M, Bedogni G, Zuccotti GV. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine 2014 Sep 29; 32(43):5657-61; PMID:25149430; http://dx.doi.org/10.1016/j.vaccine.2014.08.011
   PubMed Web of Science ®Google Scholar
• Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010 Oct 15; 202(8):1246-53; PMID:20812850; http://dx.doi.org/10.1086/656320
   PubMed Web of Science ®Google Scholar
• Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis Off Publ Infect Dis Soc Am 2014 Jul 1; 59(1):127-35; http://dx.doi.org/10.1093/cid/ciu238
   PubMed Web of Science ®Google Scholar
• Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, Durand C, Hervé C, Descamps D. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013 Nov 19; 31(48):5745-53; PMID:24091311; http://dx.doi.org/10.1016/j.vaccine.2013.09.032
   PubMed Web of Science ®Google Scholar
• Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clin Infect Dis Off Publ Infect Dis Soc Am 1997 Jun; 24(6):1139-46; http://dx.doi.org/10.1086/513642
   PubMed Web of Science ®Google Scholar
• Parent du Châtelet I, Antona D, Freymuth F, Muscat M, Halftermeyer-Zhou F, Maine C, Floret D, Lévy-Bruhl D. Spotlight on measles 2010: update on the ongoing measles outbreak in France, 2008-2010. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2010 Sep 9; 15(36):19656
   Google Scholar
• Rasmussen LD, Fonager J, Knudsen LK, Andersen PH, Rønn J, Poulsen MW, Franck KT, Fischer TK. Phylogenetic and epidemiological analysis of measles outbreaks in Denmark, 2013 to 2014. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2015; 20(39): 27–36; PMID:26537105; http://dx.doi.org/10.2807/1560-7917.ES.2015.20.39.30027
   Google Scholar
• Muscat M, Shefer A, Ben Mamou M, Spataru R, Jankovic D, Deshevoy S, Butler R, Pfeifer D. The state of measles and rubella in the WHO European Region, 2013. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2014 May; 20 (Suppl 5):12-8
   PubMed Web of Science ®Google Scholar
• Belaunzarán-Zamudio PF, García-León ML, Wong-Chew RM, Villasís-Keever A, Cuellar-Rodríguez J, Mosqueda-Gómez JL, Muñoz-Trejo T, Escobedo K, Santos JI, Ruiz-Palacios GM, et al. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. Vaccine 2009 Nov 23; 27(50):7059-64; http://dx.doi.org/10.1016/j.vaccine.2009.09.063
   PubMed Web of Science ®Google Scholar
• Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin 2010 Apr; 6(4):318-21; PMID:20372089; http://dx.doi.org/10.4161/hv.6.4.10654
   PubMed Web of Science ®Google Scholar
• Maves RC, Tripp MS, Dell TG, Bennett JW, Ahluwalia JS, Tamminga C, Baldwin JC, Starr CR, Grinkemeyer MD, Dempsey MP. Disseminated vaccine-strain varicella as initial presentation of the acquired immunodeficiency syndrome: a case report and review of the literature. J Clin Virol Off Publ Pan Am Soc Clin Virol 2014 Jan; 59(1):63-6; http://dx.doi.org/10.1016/j.jcv.2013.10.027
   Web of Science ®Google Scholar
• Grilli E, Baiocchini A, Del Nonno F, Petrosillo N, Galati V. Fulminant VZV infection in an adult AIDS patient treated with steroids: a case report. J Clin Virol Off Publ Pan Am Soc Clin Virol 2014 May; 60(1):63-6; http://dx.doi.org/10.1016/j.jcv.2014.02.008
   Web of Science ®Google Scholar
• Moanna A, Rimland D. Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era. Clin Infect Dis Off Publ Infect Dis Soc Am 2013 Jul; 57(1):122-5; http://dx.doi.org/10.1093/cid/cit165
   PubMed Web of Science ®Google Scholar
• Grabar S, Tattevin P, Selinger-Leneman H, de La Blanchardiere A, de Truchis P, Rabaud C, Rey D, Daneluzzi V, Ferret S, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis Off Publ Infect Dis Soc Am 2015 Apr 15; 60(8):1269-77; http://dx.doi.org/10.1093/cid/ciu1161
   PubMed Web of Science ®Google Scholar
• Benson C, Hua L, Andersen J, Jiang J, Bozzolo D, Annunziato P, et al. Zostavax is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo-controlled trial. 19th Conf Retroviruses Opportunistic Infect Seattle Wash [Internet]. 2012 [cited 2016 May 17]; Available from: http://scholar.google.com/scholar?cluster=15815769730375132988&hl=en&oi=scholarr
   Google Scholar
• Weinberg A, Song LY, Walker R, Allende M, Fenton T, Patterson-Bartlett J, Nachman S, Kemble G, Yi TT, Defechereux P, et al. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr 1999 Oct 2010; 55(2):189-96; http://dx.doi.org/10.1097/QAI.0b013e3181e46308
   PubMed Web of Science ®Google Scholar
• Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thail Chotmaihet Thangphaet 2002 Jan; 85(1):131-4
   PubMedGoogle Scholar
• Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, Bae HG, Litzba N, Staub T, Hatz C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis Off Publ Infect Dis Soc Am 2009 Mar 1; 48(5):659-66; http://dx.doi.org/10.1086/597006
   PubMed Web of Science ®Google Scholar
• Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev 2014; 1:CD010929; PMID:24453061
   PubMedGoogle Scholar